ISCOM-based vaccines: the second decade.
The immunostimulating complex or 'iscom' was first described 20 years ago as an antigen delivery system with powerful immunostimulating activity. Iscoms are cage-like structures, typically 40 nm in diameter, that are comprised of antigen, cholesterol, phospholipid and saponin. ISCOM-based vaccines have been shown to promote both antibody and cellular immune responses in a variety of experimental animal models. This review focuses on the evaluation of ISCOM-based vaccines in animals over the past 10 years, as well as examining the progress that has been achieved in the development of human vaccines based on ISCOM adjuvant technology.
Sanders
Megan T
MT
Department of Microbiology and Immunology, The University of Melbourne, Australia.
Brown
Lorena E
LE
Deliyannis
Georgia
G
Pearse
Martin J
MJ
D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002784:Cholesterol / Q000276:immunology; D004338:Drug Combinations; D016503:Drug Delivery Systems; D006801:Humans; D016882:ISCOMs / Q000276:immunology*; D007107:Immune System / Q000276:immunology; D051379:Mice; D008854:Microscopy, Electron; D010743:Phospholipids / Q000276:immunology; D012503:Saponins / Q000276:immunology
D000941:Antigens; D004338:Drug Combinations; C493786:ISCOMATRIX; D016882:ISCOMs; D010743:Phospholipids; D012503:Saponins; D002784:Cholesterol